TY - JOUR
T1 - Systolic heart failure: a prothrombotic state
AU - de Peuter, Olav R
AU - Kok, Wouter E M
AU - Torp-Pedersen, Christian
AU - Büller, Harry R
AU - Kamphuisen, Pieter W
AU - de Peuter, Olav R
AU - Kok, Wouter E M
AU - Torp-Pedersen, Christian
AU - Büller, Harry R
AU - Kamphuisen, Pieter W
N1 - Keywords: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Fibrinolytic Agents; Heart Failure, Systolic; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Embolism; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renin-Angiotensin System; Thromboembolism; Warfarin
PY - 2009/7/1
Y1 - 2009/7/1
N2 - Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic state in heart failure. This article focuses on this prothrombotic state and discusses the risk of thromboembolic events, pathophysiological mechanisms, and the potential role of anticoagulant treatment.
AB - Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic state in heart failure. This article focuses on this prothrombotic state and discusses the risk of thromboembolic events, pathophysiological mechanisms, and the potential role of anticoagulant treatment.
U2 - 10.1055/s-0029-1234145
DO - 10.1055/s-0029-1234145
M3 - Journal article
C2 - 19739040
VL - 35
SP - 497
EP - 504
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
SN - 0094-6176
IS - 5
ER -